P1: PSB Printer: Yet To Come
9780521704632ind CUFX213A/Peck 9780521618168 December 29, 2007 17:19
365 Indexaztreonam use during, 318
cephalosporin use during, 316
imipenem use during, 317
macrolide use during, 319
penicillin use during, 313
teicoplanin use during, 323
zidovudine use during, 334
corticosteroidsseeglucocorticoid(s); steroids
corticotrophin-releasing hormone, 354
cortisone, 31
covalent bonds, 85
COX inhibitors, non-specific,152t,
153 –158
COX-1, aspirin actions, 38
COX-1 inhibitors, 337
COX-2 inhibitors
preferential,152t, 158–159
specific,152t, 159–162
structure,159f
cranial nerves, 197
creatinine clearance, 21
elderly people, 23
neonates, 23
critical illness myopathy
critical volume hypothesis, 99 –100
crystalloids, 300
cyanide, 246 –247
poisoning, 24
toxicity, 246 , 248–249
cyclizine, 289 –290
cyclodextrin(s), 196
γcyclodextrin, 24 , 196
cyclohexanol group, 94
cyclo-oxygenase (COX), 149 –151
see alsoCOX inhibitors, non-specific; COX-1;
COX-2 inhibitors
cytochrome P450 system,18t, 41–42
inhaled anaesthetics, 117
neonates, 23
repaglinide, 351
thiazolidinediones, 351δreceptors, 137
dalteparin, 341 –342
dantrolene
kinetics, 183 –184
malignant hyperthermia treatment, 182 –184
mechanism of action, 183
DC cardioversion, digoxin, 232
decrement time for TCI, 83
depolarization, sino-atrial node, 228
depot preparations, 12
desensitization, 39
desflurane, 114 , 126t, 127t
dexamethasone, 291 , 353dexketoprofen, enantiopure preparations,
49
dexmedetomidine, 267 –268
enantiopure preparations, 49
dextrans 40 and 70, 339
dextrose
infusion, 352
interaction with insulin, 40
diabetes
glucocorticoid-induced, 353
peri-operative patient care,
351 –352
thiazide diuretics, 306 –307
diabetes mellitus, sulphonylureas, 349
diacylglycerol (DAG), 28 –30
diamorphine, 91 , 142
intrathecal, lipid solubility, 6
kinetics, 142
presentation, 142
uses, 142
diastereoisomers, 48
diazepam, 272
metabolism,273f
diazoxide, 256 –257
dibucaine, 183 –184
diclofenac, 156
effects, 156
presentation, 156
uses, 156
dicobalt edetate, 24 , 41, 248–249
differentiation, 51 , 60, 60f, 62
diffusion rate
concentration gradient, 5
factors influencing,5–7
ionization,5–6
lipid solubility, 6
molecular size, 5
protein binding, 7
digoxin, 230 –233
drug interactions, 232
hypokalaemia risk, 306 –307
kinetics, 232
mechanism of action, 231
presentation, 230
side-effects, 232
toxicity, 229 , 232
treatment, 232 –233, 245
uses, 231
dihydrocodeine, 45 , 144
diltiazem, 254 –255
dipyridamole, 337
diseases
bioavailability influence, 9
co-existing in elderly people, 23
effects on drug actions, 21 –22